Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Eylea's Challenges | Explore Regeneron's strategy to maintain Eylea's market position amid biosimilar competition and regulatory hurdles, impacting its $4 billion franchise |
Dupixent's Ascent | Discover how Dupixent's expansion into new indications could drive Regeneron's growth, with analysts projecting an 8% CAGR from 2025 to 2030 |
Pipeline Potential | Delve into Regeneron's promising oncology and immunology pipeline, including fianlimab for melanoma and itepekimab for COPD |
Financial Outlook | Analysts maintain a positive outlook with EPS estimates around $34.50 for 2025. Price targets range from $695 to $1,215, averaging around $990 |
Metrics to compare | REGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREGNPeersSector | |
---|---|---|---|---|
P/E Ratio | 12.1x | −2.7x | −0.4x | |
PEG Ratio | 0.73 | 0.00 | 0.00 | |
Price/Book | 1.8x | 2.6x | 2.6x | |
Price / LTM Sales | 3.9x | 4.2x | 3.0x | |
Upside (Analyst Target) | 46.1% | 32.5% | 52.3% | |
Fair Value Upside | Unlock | 29.9% | 9.4% | Unlock |